Nasus Pharma (NSRX) Assets Average (2025)
Nasus Pharma (NSRX) reported Assets Average of $2.8 million for Q4 2025, up 316.15% quarter-over-quarter from $678000.0 in Q2 2025.
Nasus Pharma (NSRX) Assets Average (2025) Analysis & Trends
Nasus Pharma has reported Assets Average for 1 years, with the latest figure at $2.8 million in Q4 2025.
- For the quarter ending Q4 2025, Assets Average changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (changed N/A YoY), and the FY2025 full-year result was $2.9 million, changed N/A from the prior year.
- Assets Average for Q4 2025 stood at $2.8 million, up from $678000.0 in the prior quarter.
- The five-year high for Assets Average was $2.8 million in Q4 2025, with the low at $678000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 2.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.82 Mn |
| Jun 30, 2025 | 678,000.00 |